<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antifungals: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int288-antifungals.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int288-antifungals.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int288-antifungals.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int287-vigabatrin.htm" title="Previous: Vigabatrin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1125-micafungin.htm" title="Next: Micafungin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Antifungals</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Antifungals</strong> has no specific interaction information.</p><p><strong>Micafungin</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span></span> <span>micafungin</span> <span>possibly increases plasma concentration of</span> <span>amphotericin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>micafungin</span> <span>possibly increases plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span></span> <span>micafungin</span> <span>increases plasma concentration of</span> <span>itraconazole</span> <span>(consider reducing dose of <span>itraconazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span></span> <span>micafungin</span> <span>increases plasma concentration of</span> <span>nifedipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td><p><span></span> <span>micafungin</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Caspofungin</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>caspofungin</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>caspofungin</span> <span>increased by</span> <span>ciclosporin</span> <span>(manufacturer of <span>caspofungin</span> recommends monitoring liver enzymes)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int490-dexamethasone.htm">Dexamethasone</a></td><td><p><span>plasma concentration of </span> <span>caspofungin</span> <span>possibly reduced by</span> <span>dexamethasone</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>caspofungin</span> <span>possibly reduced by</span> <span>efavirenz</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>caspofungin</span> <span>possibly reduced by</span> <span>nevirapine</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>caspofungin</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>—consider increasing dose of <span>caspofungin</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span> <span>caspofungin</span> <span>initially increased and then reduced by</span> <span>rifampicin</span> <span>(consider increasing dose of <span>caspofungin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>caspofungin</span> <span>reduces plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr></tbody></table><p><strong>Antifungals, Polyene</strong> belongs to <strong>Antifungals</strong> but has no specific interaction information.</p><p><strong>Amphotericin</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int128-aminoglycosides.htm">Aminoglycosides</a></td><td><p><span>increased risk of nephrotoxicity when </span> <span>amphotericin</span> <span>given with</span> <span>aminoglycosides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td><p><span>effects of </span> <span>amphotericin</span> <span>possibly antagonised by</span> <span>imidazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td><p><span>effects of </span> <span>amphotericin</span> <span>possibly antagonised by</span> <span>triazoles</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amphotericin</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int478-cardiac-glycosides.htm">Cardiac Glycosides</a></td><td class="cAI"><p><span>hypokalaemia caused by </span> <span>amphotericin</span> <span>increases cardiac toxicity with</span> <span>cardiac glycosides</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>amphotericin</span> <span>given with</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td class="cAI"><p><span>increased risk of hypokalaemia when </span> <span>amphotericin</span> <span>given with</span> <span>corticosteroids</span> <span>—avoid concomitant use unless <span>corticosteroids</span> needed to control reactions</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int539-diuretics-loop.htm">Diuretics, Loop</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>amphotericin</span> <span>given with</span> <span>loop diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int525-diuretics-thiazide-and-related.htm">Diuretics, Thiazide and related</a></td><td><p><span>increased risk of hypokalaemia when </span> <span>amphotericin</span> <span>given with</span> <span>thiazides and related diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int820-flucytosine.htm">Flucytosine</a></td><td><p><span></span> <span>amphotericin</span> <span>reduces renal excretion and increases cellular uptake of</span> <span>flucytosine</span> <span>(toxicity possibly increased)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1125-micafungin.htm">Micafungin</a></td><td><p><span>plasma concentration of </span> <span>amphotericin</span> <span>possibly increased by</span> <span>micafungin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td><p><span>possible increased risk of nephrotoxicity when </span> <span>amphotericin</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int189-polymyxins.htm">Polymyxins</a></td><td><p><span>increased risk of nephrotoxicity when </span> <span>amphotericin</span> <span>given with</span> <span>polymyxins</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>increased risk of nephrotoxicity when </span> <span>amphotericin</span> <span>given with</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int218-vancomycin.htm">Vancomycin</a></td><td><p><span>possible increased risk of nephrotoxicity when </span> <span>amphotericin</span> <span>given with</span> <span>vancomycin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Flucytosine</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span>renal excretion of </span> <span>flucytosine</span> <span>decreased and cellular uptake increased by</span> <span>amphotericin</span> <span>(toxicity possibly increased)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int821-cytarabine.htm">Cytarabine</a></td><td><p><span>plasma concentration of </span> <span>flucytosine</span> <span>possibly reduced by</span> <span>cytarabine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Griseofulvin</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span></span> <span>griseofulvin</span> <span>possibly enhances effects of</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>griseofulvin</span> <span>possibly reduces plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>griseofulvin</span> <span>reduces anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>anecdotal reports of contraceptive failure and menstrual irregularities when </span> <span>griseofulvin</span> <span>given with</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>absorption of </span> <span>griseofulvin</span> <span>reduced by</span> <span>phenobarbital</span> <span>(reduced effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td><p><span>anecdotal reports of contraceptive failure and menstrual irregularities when </span> <span>griseofulvin</span> <span>given with</span> <span>progestogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr></tbody></table><p><strong>Terbinafine</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span></span> <span>terbinafine</span> <span>possibly increases plasma concentration of</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td><p><span></span> <span>terbinafine</span> <span>possibly reduces plasma concentration of</span> <span>ciclosporin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span> <span>terbinafine</span> <span>increased by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int301-fluconazole.htm">Fluconazole</a></td><td><p><span></span> <span>terbinafine</span> <span>increases plasma concentration of</span> <span>fluconazole</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>occasional reports of breakthrough bleeding when </span> <span>terbinafine</span> <span>given with</span> <span>oestrogens</span> <span>(when used for contraception)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td><p><span>occasional reports of breakthrough bleeding when </span> <span>terbinafine</span> <span>given with</span> <span>progestogens</span> <span>(when used for contraception)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>terbinafine</span> <span>reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Antifungals, Imidazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span></span> <span>imidazoles</span> <span>possibly antagonise effects of</span> <span>amphotericin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>imidazoles</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>imidazoles</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span> <span>imidazoles</span> <span>given with</span> <span>ergotamine and methysergide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>imidazoles</span> <span>possibly inhibit metabolism of</span> <span>mizolastine</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>anecdotal reports of contraceptive failure when </span> <span>imidazoles</span> <span>given with</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>imidazoles</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>imidazoles</span> <span>possibly increase plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span> <span>imidazoles</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>imidazoles</span> <span>possibly increase plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>imidazoles</span> <span>possibly increase plasma concentration of</span> <span>tacrolimus</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr></tbody></table><p><strong>Ketoconazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int30-alfuzosin.htm">Alfuzosin</a></td><td><p><span></span> <span>ketoconazole</span> <span>possibly increases plasma concentration of</span> <span>alfuzosin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>aliskiren</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1124-alitretinoin.htm">Alitretinoin</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>alitretinoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int925-almotriptan.htm">Almotriptan</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>almotriptan</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>alprazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>ketoconazole</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>absorption of </span> <span>ketoconazole</span> <span>reduced by</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>apixaban</span> <span>—manufacturer of <span>apixaban</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1116-bortezomib.htm">Bortezomib</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>bortezomib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>bosentan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int496-budesonide.htm">Budesonide</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of inhaled and oral</span> <span>budesonide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int87-buprenorphine.htm">Buprenorphine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>buprenorphine</span> <span>(reduce dose of <span>buprenorphine</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>ketoconazole</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int469-calcium-channel-blockers-dihydropyridines.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td><p><span></span> <span>ketoconazole</span> <span>possibly inhibits metabolism of</span> <span>dihydropyridines</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span></span> <span>ketoconazole</span> <span>possibly increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1043-ciclesonide.htm">Ciclesonide</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of active metabolite of</span> <span>ciclesonide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int940-cilostazol.htm">Cilostazol</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>cilostazol</span> <span>(consider reducing dose of <span>cilostazol</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1022-cinacalcet.htm">Cinacalcet</a></td><td><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>cinacalcet</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>ketoconazole</span> <span>possibly inhibits metabolism of</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>darifenacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of both drugs increased when </span> <span>ketoconazole</span> <span>given with</span> <span>darunavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1077-dasatinib.htm">Dasatinib</a></td><td><p><span></span> <span>ketoconazole</span> <span>possibly increases plasma concentration of</span> <span>dasatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>ketoconazole</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int516-docetaxel.htm">Docetaxel</a></td><td><p><span>in vitro studies suggest a possible interaction between </span> <span>ketoconazole</span> <span>and</span> <span>docetaxel</span> <span>(consult <span>docetaxel</span> product literature)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td class="cAI"><p><span>manufacturer of </span> <span>ketoconazole</span> <span>advises avoid concomitant use with</span> <span>domperidone</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>dronedarone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1048-erlotinib.htm">Erlotinib</a></td><td><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>erlotinib</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>everolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int471-felodipine.htm">Felodipine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>felodipine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of fesoterodine advises dose reduction when </span> <span>ketoconazole</span> <span>given with</span> <span>fesoterodine</span> <span>—consult <span>fesoterodine</span> product literature</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1226-fidaxomicin.htm">Fidaxomicin</a></td><td><p><span>avoidance of </span> <span>ketoconazole</span> <span>advised by manufacturer of</span> <span>fidaxomicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1202-fingolimod.htm">Fingolimod</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>fingolimod</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int497-fluticasone.htm">Fluticasone</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of inhaled</span> <span>fluticasone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>plasma concentration of </span> <span>ketoconazole</span> <span>increased by</span> <span>fosamprenavir</span> <span>(also plasma concentration of <span>fosamprenavir</span> possibly increased)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int915-galantamine.htm">Galantamine</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>galantamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span> <span>ketoconazole</span> <span>reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int933-imatinib.htm">Imatinib</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>imatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>indinavir</span> <span>(consider reducing dose of <span>indinavir</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1006-irinotecan.htm">Irinotecan</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>reduces plasma concentration of </span> <span>irinotecan</span> <span>(but concentration of active metabolite of irinotecan increased)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td><p><span>plasma concentration of </span> <span>ketoconazole</span> <span>possibly reduced by</span> <span>isoniazid</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1092-lanthanum.htm">Lanthanum</a></td><td><p><span>absorption of  </span> <span>ketoconazole</span> <span>possibly reduced by</span> <span>lanthanum</span> <span>(give at least 2 hours apart)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>lapatinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span> <span>ketoconazole</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int309-loratadine.htm">Loratadine</a></td><td><p><span>manufacturer of loratadine advises </span> <span>ketoconazole</span> <span>possibly increases plasma concentration of</span> <span>loratadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1107-maraviroc.htm">Maraviroc</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>maraviroc</span> <span>(consider reducing dose of <span>maraviroc</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>mefloquine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>ketoconazole</span> <span>inhibits the metabolism of</span> <span>methylprednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>mirtazapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int968-mometasone.htm">Mometasone</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of inhaled</span> <span>mometasone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ketoconazole</span> <span>reduced by</span> <span>nevirapine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>nilotinib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1093-paricalcitol.htm">Paricalcitol</a></td><td><p><span></span> <span>ketoconazole</span> <span>possibly increases plasma concentration of</span> <span>paricalcitol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>ketoconazole</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>ketoconazole</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>absorption of </span> <span>ketoconazole</span> <span>reduced by</span> <span>proton pump inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>ranolazine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>ketoconazole</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration), also plasma concentration of <span>rifampicin</span> may be reduced by <span>ketoconazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>combination of </span> <span>ketoconazole</span> <span>with</span> <span>ritonavir</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>rivaroxaban</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1155-rupatadine.htm">Rupatadine</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>rupatadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int727-salmeterol.htm">Salmeterol</a></td><td><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>salmeterol</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>sildenafil</span> <span>—reduce initial dose of <span>sildenafil</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>ketoconazole</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1020-solifenacin.htm">Solifenacin</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>solifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span> <span>ketoconazole</span> <span>reduced by</span> <span>sucralfate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1075-sunitinib.htm">Sunitinib</a></td><td><p><span></span> <span>ketoconazole</span> <span>inhibits metabolism of</span> <span>sunitinib</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>tadalafil</span> <span>—manufacturer of <span>tadalafil</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of both drugs possibly increased when </span> <span>ketoconazole</span> <span>given with</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>avoidance of concomitant </span> <span>ketoconazole</span> <span>in severe renal and hepatic impairment advised by manufacturer of</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1137-temsirolimus.htm">Temsirolimus</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of active metabolite of</span> <span>temsirolimus</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> The main active metabolite of temsirolimus is sirolimus—see also interactions of sirolimus and consult product literature</p></div></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>ticagrelor</span> <span>—manufacturer of <span>ticagrelor</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span> <span>ketoconazole</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1158-tolvaptan.htm">Tolvaptan</a></td><td><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>tolvaptan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int819-tretinoin.htm">Tretinoin</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>possibly increases risk of</span> <span>tretinoin</span> <span>toxicity</span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>vardenafil</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>ketoconazole</span> <span>increases plasma concentration of</span> <span>vinflunine</span> <span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Miconazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span></span> <span>miconazole</span> <span>possibly increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>possibly inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span>(<span>miconazole</span> oral gel and possibly vaginal and topical formulations absorbed)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int271-gliclazide.htm">Gliclazide</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>enhances hypoglycaemic effect of</span> <span>gliclazide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int272-glipizide.htm">Glipizide</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>enhances hypoglycaemic effect of</span> <span>glipizide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>enhances anticonvulsant effect of</span> <span>phenytoin</span> <span>(plasma concentration of <span>phenytoin</span> increased)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span> <span>miconazole</span> <span>given with</span> <span>simvastatin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>miconazole</span> <span>increases plasma concentration of</span> <span>sulfonylureas</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Antifungals, Triazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int290-amphotericin.htm">Amphotericin</a></td><td><p><span></span> <span>triazoles</span> <span>possibly antagonise effects of</span> <span>amphotericin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Close monitoring required with concomitant administration of nephrotoxic drugs or cytotoxics</p></div></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>triazoles</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>triazoles</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int563-ergotamine-and-methysergide.htm">Ergotamine and Methysergide</a></td><td class="cAI"><p><span>increased risk of ergotism when </span> <span>triazoles</span> <span>given with</span> <span>ergotamine and methysergide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int95-fentanyl.htm">Fentanyl</a></td><td class="cAI"><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>fentanyl</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>triazoles</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int824-quetiapine.htm">Quetiapine</a></td><td class="cAI"><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>quetiapine</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span> <span>triazoles</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td><p><span></span> <span>triazoles</span> <span>possibly increase plasma concentration of</span> <span>saquinavir</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Posaconazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span> <span>posaconazole</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>increases plasma concentration of</span> <span>atazanavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>posaconazole</span> <span>given with</span> <span>atorvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>reduced by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>posaconazole</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>plasma concentration of </span> <span>posaconazole</span> <span>possibly reduced by</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int272-glipizide.htm">Glipizide</a></td><td><p><span></span> <span>posaconazole</span> <span>possibly enhances hypoglycaemic effect of</span> <span>glipizide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>manufacturer of </span> <span>posaconazole</span> <span>advises avoid concomitant use with</span> <span>histamine H<sub>2</sub>-antagonists</span> <span>(plasma concentration of <span>posaconazole</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>posaconazole</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>manufacturer of </span> <span>posaconazole</span> <span>advises avoid concomitant use with</span> <span>proton pump inhibitors</span> <span>(plasma concentration of <span>posaconazole</span> possibly reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(also plasma concentration of <span>posaconazole</span> reduced)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span> <span>posaconazole</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>posaconazole</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td><p><span></span> <span>posaconazole</span> <span>possibly increases plasma concentration of</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>posaconazole</span> <span>possibly increased by</span> <span>telaprevir</span> <span>(increased risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1002-vinblastine.htm">Vinblastine</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>possibly inhibits metabolism of</span> <span>vinblastine</span> <span>(increased risk of neurotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int815-vincristine.htm">Vincristine</a></td><td class="cAI"><p><span></span> <span>posaconazole</span> <span>possibly inhibits metabolism of</span> <span>vincristine</span> <span>(increased risk of neurotoxicity)</span>  </p></td><td></td></tr></tbody></table><p><strong>Voriconazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>alfentanil</span> <span>(consider reducing dose of <span>alfentanil</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>diazepam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int64-diclofenac.htm">Diclofenac</a></td><td><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>diclofenac</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>reduced by</span> <span>efavirenz</span> <span>, also plasma concentration of <span>efavirenz</span> increased (increase <span>voriconazole</span> dose and reduce <span>efavirenz</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int914-esomeprazole.htm">Esomeprazole</a></td><td><p><span></span> <span>voriconazole</span> <span>possibly increases plasma concentration of</span> <span>esomeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int783-ibuprofen.htm">Ibuprofen</a></td><td><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>ibuprofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>methadone</span> <span>(consider reducing dose of <span>methadone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>nilotinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>plasma concentration of </span> <span>voriconazole</span> <span>increased by</span> <span>oestrogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>omeprazole</span> <span>(consider reducing dose of <span>omeprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int901-oxycodone.htm">Oxycodone</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>oxycodone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>, also <span>phenytoin</span> reduces plasma concentration of <span>voriconazole</span> (increase dose of <span>voriconazole</span> and also monitor for <span>phenytoin</span> toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td><p><span>plasma concentration of </span> <span>voriconazole</span> <span>possibly increased by</span> <span>progestogens</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>, also <span>rifabutin</span> reduces plasma concentration of <span>voriconazole</span> (increase dose of <span>voriconazole</span> and also monitor for <span>rifabutin</span> toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>reduced by</span> <span>rifampicin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>reduced by</span> <span>ritonavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span> <span>voriconazole</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td><p><span>possible increased risk of myopathy when </span> <span>voriconazole</span> <span>given with</span> <span>simvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>reduced by</span> <span>St John's wort</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>voriconazole</span> <span>possibly increases plasma concentration of</span> <span>sulfonylureas</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>voriconazole</span> <span>possibly affected by</span> <span>telaprevir</span> <span>(possible increased risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int819-tretinoin.htm">Tretinoin</a></td><td class="cAI"><p><span></span> <span>voriconazole</span> <span>possibly increases risk of</span> <span>tretinoin</span> <span>toxicity</span>  </p></td><td></td></tr></tbody></table><p><strong>Fluconazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> In general, fluconazole interactions relate to multiple-dose treatment</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>fluconazole</span> <span>inhibits metabolism of</span> <span>alfentanil</span> <span>(risk of prolonged or delayed respiratory depression)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int242-amitriptyline.htm">Amitriptyline</a></td><td><p><span></span> <span>fluconazole</span> <span>possibly increases plasma concentration of</span> <span>amitriptyline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>possibly increases plasma concentration of</span> <span>bosentan</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span></span> <span>fluconazole</span> <span>possibly increases plasma concentration of</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int898-celecoxib.htm">Celecoxib</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>celecoxib</span> <span>(halve dose of <span>celecoxib</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int502-cyclophosphamide.htm">Cyclophosphamide</a></td><td><p><span></span> <span>fluconazole</span> <span>possibly increases side-effects of</span> <span>cyclophosphamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int412-diazepam.htm">Diazepam</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>diazepam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>(reduce dose of <span>eplerenone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>manufacturer of </span> <span>fluconazole</span> <span>advises avoid concomitant use with</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int69-flurbiprofen.htm">Flurbiprofen</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>flurbiprofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int603-fluvastatin.htm">Fluvastatin</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>fluvastatin</span> <span>—possible increased risk of myopathy</span>  </p></td><td></td></tr><tr><td><a href="bnf_int530-hydrochlorothiazide.htm">Hydrochlorothiazide</a></td><td><p><span>plasma concentration of </span> <span>fluconazole</span> <span>increased by</span> <span>hydrochlorothiazide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int783-ibuprofen.htm">Ibuprofen</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>ibuprofen</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>ivabradine</span> <span>—reduce initial dose of <span>ivabradine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int920-nateglinide.htm">Nateglinide</a></td><td><p><span></span> <span>fluconazole</span> <span>possibly enhances hypoglycaemic effect of</span> <span>nateglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>nevirapine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int249-nortriptyline.htm">Nortriptyline</a></td><td><p><span></span> <span>fluconazole</span> <span>possibly increases plasma concentration of</span> <span>nortriptyline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int961-parecoxib.htm">Parecoxib</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>parecoxib</span> <span>(reduce dose of <span>parecoxib</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span>(consider reducing dose of <span>phenytoin</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>rifabutin</span> <span>(increased risk of uveitis—reduce <span>rifabutin</span> dose)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>fluconazole</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>possible increased risk of myopathy when </span> <span>fluconazole</span> <span>given with</span> <span>simvastatin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td><p><span></span> <span>fluconazole</span> <span>possibly increases plasma concentration of</span> <span>sirolimus</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>sulfonylureas</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int292-terbinafine.htm">Terbinafine</a></td><td><p><span>plasma concentration of </span> <span>fluconazole</span> <span>increased by</span> <span>terbinafine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>possibly increases plasma concentration of</span> <span>theophylline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>tipranavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int819-tretinoin.htm">Tretinoin</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>possibly increases risk of</span> <span>tretinoin</span> <span>toxicity</span>  </p></td><td></td></tr><tr><td><a href="bnf_int403-zidovudine.htm">Zidovudine</a></td><td class="cAI"><p><span></span> <span>fluconazole</span> <span>increases plasma concentration of</span> <span>zidovudine</span> <span>(increased risk of toxicity)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</p></div></td></tr></tbody></table><p><strong>Itraconazole</strong> belongs to <strong>Antifungals</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int86-alfentanil.htm">Alfentanil</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>alfentanil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1099-aliskiren.htm">Aliskiren</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>aliskiren</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>alprazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>itraconazole</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int1217-apixaban.htm">Apixaban</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>apixaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int601-atorvastatin.htm">Atorvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>itraconazole</span> <span>given with</span> <span>atorvastatin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int943-bosentan.htm">Bosentan</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>bosentan</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int496-budesonide.htm">Budesonide</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of inhaled</span> <span>budesonide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>buspirone</span> <span>(reduce dose of <span>buspirone</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int993-busulfan.htm">Busulfan</a></td><td><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>busulfan</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1204-cabazitaxel.htm">Cabazitaxel</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>cabazitaxel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>negative inotropic effect possibly increased when </span> <span>itraconazole</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int469-calcium-channel-blockers-dihydropyridines.htm">Calcium-channel Blockers (dihydropyridines)</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>dihydropyridines</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int499-ciclosporin.htm">Ciclosporin</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>ciclosporin</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>increased by</span> <span>clarithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int483-colchicine.htm">Colchicine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases risk of</span> <span>colchicine</span> <span>toxicity—suspend or reduce dose of <span>colchicine</span> (avoid concomitant use in hepatic or renal impairment)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int484-corticosteroids.htm">Corticosteroids</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>corticosteroids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</p></div></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>enhances anticoagulant effect of</span> <span>coumarins</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int502-cyclophosphamide.htm">Cyclophosphamide</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases side-effects of</span> <span>cyclophosphamide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>dabigatran etexilate</span> <span>—manufacturer of <span>dabigatran etexilate</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>darifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int480-digoxin.htm">Digoxin</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>digoxin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>manufacturer of </span> <span>itraconazole</span> <span>advises avoid concomitant use with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>efavirenz</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int963-eletriptan.htm">Eletriptan</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>eletriptan</span> <span>(risk of toxicity)—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1025-eplerenone.htm">Eplerenone</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>eplerenone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1169-everolimus.htm">Everolimus</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>everolimus</span> <span>—manufacturer of <span>everolimus</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int471-felodipine.htm">Felodipine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>felodipine</span> <span>(increased plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1119-fesoterodine.htm">Fesoterodine</a></td><td><p><span>manufacturer of fesoterodine advises dose reduction when </span> <span>itraconazole</span> <span>given with</span> <span>fesoterodine</span> <span>—consult <span>fesoterodine</span> product literature</span>  </p></td><td></td></tr><tr><td><a href="bnf_int497-fluticasone.htm">Fluticasone</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of inhaled</span> <span>fluticasone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td><p><span>plasma concentration of both drugs may increase when </span> <span>itraconazole</span> <span>given with</span> <span>fosamprenavir</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int1170-gefitinib.htm">Gefitinib</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>gefitinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int743-histamine-h-2-antagonists.htm">Histamine H<sub>2</sub>-antagonists</a></td><td><p><span>absorption of </span> <span>itraconazole</span> <span>reduced by</span> <span>histamine H<sub>2</sub>-antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>indinavir</span> <span>(consider reducing dose of <span>indinavir</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>ivabradine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int846-lercanidipine.htm">Lercanidipine</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>lercanidipine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int492-methylprednisolone.htm">Methylprednisolone</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>methylprednisolone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1125-micafungin.htm">Micafungin</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>increased by</span> <span>micafungin</span> <span>(consider reducing dose of <span>itraconazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int421-midazolam.htm">Midazolam</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>midazolam</span> <span>(risk of prolonged sedation)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int841-mizolastine.htm">Mizolastine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>inhibits metabolism of</span> <span>mizolastine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly reduced by</span> <span>nevirapine</span> <span>—consider increasing dose of <span>itraconazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1118-nilotinib.htm">Nilotinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>nilotinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1186-pazopanib.htm">Pazopanib</a></td><td class="cAI"><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>pazopanib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>phenytoin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int751-proton-pump-inhibitors.htm">Proton Pump Inhibitors</a></td><td><p><span>absorption of </span> <span>itraconazole</span> <span>reduced by</span> <span>proton pump inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>ranolazine</span> <span>—manufacturer of <span>ranolazine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int855-repaglinide.htm">Repaglinide</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly enhances hypoglycaemic effect of</span> <span>repaglinide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>rifabutin</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>itraconazole</span> <span>reduced by</span> <span>rifampicin</span> <span>—manufacturer of <span>itraconazole</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>combination of </span> <span>itraconazole</span> <span>with</span> <span>ritonavir</span> <span>may increase plasma concentration of either drug (or both)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1136-rivaroxaban.htm">Rivaroxaban</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>rivaroxaban</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int858-sildenafil.htm">Sildenafil</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>sildenafil</span> <span>—reduce initial dose of <span>sildenafil</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int605-simvastatin.htm">Simvastatin</a></td><td class="cAI"><p><span>increased risk of myopathy when </span> <span>itraconazole</span> <span>given with</span> <span>simvastatin</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int921-sirolimus.htm">Sirolimus</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>sirolimus</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1020-solifenacin.htm">Solifenacin</a></td><td><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>solifenacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>increases plasma concentration of</span> <span>tacrolimus</span> <span>(consider reducing dose of <span>tacrolimus</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int945-tadalafil.htm">Tadalafil</a></td><td><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>tadalafil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td><p><span>plasma concentration of </span> <span>itraconazole</span> <span>possibly increased by</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int850-tolterodine.htm">Tolterodine</a></td><td><p><span>avoidance of </span> <span>itraconazole</span> <span>advised by manufacturer of</span> <span>tolterodine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int967-vardenafil.htm">Vardenafil</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>vardenafil</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int815-vincristine.htm">Vincristine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>vincristine</span> <span>(increased risk of neurotoxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1181-vinflunine.htm">Vinflunine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly increases plasma concentration of</span> <span>vinflunine</span> <span>—manufacturer of <span>vinflunine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1085-vinorelbine.htm">Vinorelbine</a></td><td class="cAI"><p><span></span> <span>itraconazole</span> <span>possibly inhibits metabolism of</span> <span>vinorelbine</span> <span>(increased risk of neurotoxicity)</span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1125-micafungin.htm" title="Micafungin">Micafungin</a></li><li><a href="bnf_int947-caspofungin.htm" title="Caspofungin">Caspofungin</a></li><li id="_bnf_int289-antifungals-polyene"><a href="bnf_int289-antifungals-polyene.htm" title="Antifungals, Polyene">Antifungals, Polyene</a></li><li><a href="bnf_int820-flucytosine.htm" title="Flucytosine">Flucytosine</a></li><li><a href="bnf_int291-griseofulvin.htm" title="Griseofulvin">Griseofulvin</a></li><li><a href="bnf_int292-terbinafine.htm" title="Terbinafine">Terbinafine</a></li><li id="_bnf_int293-antifungals-imidazole"><a href="bnf_int293-antifungals-imidazole.htm" title="Antifungals, Imidazole">Antifungals, Imidazole</a></li><li id="_bnf_int300-antifungals-triazole"><a href="bnf_int300-antifungals-triazole.htm" title="Antifungals, Triazole">Antifungals, Triazole</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int287-vigabatrin.htm">Previous: Vigabatrin</a> | <a class="top" href="bnf_int288-antifungals.htm#">Top</a> | <a accesskey="]" href="bnf_int1125-micafungin.htm">Next: Micafungin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>